COVID-19 Vaccine – Official Arlington County Virginia Government Website



Information on vaccines for the general public

Anyone 6 months and older is eligible for a FREE COVID-19 vaccine.

  • All Virginians are encouraged to get vaccinated to protect themselves, their loved ones and their communities.
  • Vaccines offer the best form of protection against COVID-19.
  • Getting most Virginians vaccinated is the best way to end the pandemic and get back to normal.

Visit the Arlington County Division of Public Health’s COVID-19 Immunization Clinic Scheduling page for specific information and details on how to get your vaccine.

Remember that getting the COVID-19 vaccine is only part of the effort to reduce the spread of the virus. Even after being vaccinated, you will still need to practice preventive measures.

COVID-19 vaccination schedule for the general population (most people) (last updated 06/24/2022)

The Food and Drug Administration (FDA) maintains a list of all approved and authorized products. Vaccines against covid-19. Talk to your health care provider about additional tips. The COVID-19 vaccination schedule for moderately and severely immunocompromised people is provided in a separate table after the COVID-19 vaccination schedule for the general population (most people). The The CDC maintains a current COVID-19 vaccination schedule for most people and people who are moderately or severely immunocompromised.

COVID-19 vaccination schedule for the general population (most people)
Vaccines against covid19* Approved ages Vaccination schedule
mRNA vaccines:**
Pfizer-BioNTech 6 months-4 years

3 doses total

Primary vaccination in 3 doses (3 to 8 weeks between doses 1 and 2; at least 8 weeks between doses 2 and 3)

A booster dose is currently not recommended

Pfizer-BioNTech (12+ Community)

5-49 years old

3 doses total

2-dose primary series (3-8 weeks between doses)

A single booster dose is recommended 5 months or more after the primary series

Pfizer-BioNTech (Community) 50 years and over

4 doses total

2-dose primary series (3-8 weeks between doses)

A 2-dose booster series is recommended:

  • The first booster dose is recommended at least 5 months after the primary vaccination
  • The second booster dose is recommended using an mRNA vaccine at least 4 months after the first booster dose
Modern

6 months-17 years

2 total doses

2-dose primary series (4-8 weeks between doses)

A booster dose is currently not recommended

Modern (Spikevax) 18-49 years old

3 doses total

2-dose primary series (4-8 weeks between doses)

A single booster dose is recommended at least 5 months after the primary vaccination

Modern (Spikevax) 50 years and over

4 doses total

2-dose primary series (4 weeks between doses)

A 2-dose booster series is recommended:

  • The first booster dose is recommended at least 5 months after the primary vaccination
  • The second booster dose is recommended using an mRNA vaccine at least 4 months after the first booster dose
Anyone unable or unwilling to receive the mRNA vaccine
Johnson and Johnson (Janssen)

Viral vector vaccine

18-49 years old

2 total doses

1-dose primary series

A single booster dose^ is recommended at least 2 months after the primary series

^ Individuals 18-49 years of age who are not moderately or severely immunocompromised and who have received a Johnson & Johnson (J&J) primary vaccine and a J&J booster dose may receive a second booster dose using an mRNA vaccine at least 4 months after their first J&J booster dose.

Johnson and Johnson (Janssen)

Viral vector vaccine

50 years and over

3 doses total

1-dose primary series

A 2-dose booster series is recommended:

  • The first booster dose is recommended at least 2 months after the primary vaccination
  • The second booster dose is recommended using an mRNA vaccine at least 4 months after the first booster dose

* The CDC recommends mRNA vaccines (Pfizer and Moderna) over the Johnson & Johnson (J&J)/Janssen COVID-19 vaccine for people age 18 and older. Anyone unable or unwilling to receive an mRNA vaccine can request the Johnson & Johnson COVID-19 vaccine. You can choose which COVID-19 vaccine to receive as the primary series and as the booster dose. Talk to your health care provider for further advice.

** Some people ages 12 and older, especially men ages 12 to 39, may want to consult with their health care provider about the length of the interval between the first and second dose of the mRNA vaccine series based on each patient’s risk-benefit profile. (see CDC guidance for more information)

COVID-19 Vaccination Schedule for Moderately or Severely Immunocompromised Individuals (last updated 06/24/2022)

The Food and Drug Administration (FDA) maintains a list of all approved and authorized products. Vaccines against covid-19. The Centers for Disease Control and Prevention (CDC) provides vaccination advice for people who moderately or severely immunocompromised. Talk to your health care provider about additional tips. The COVID-19 vaccination schedule for the general population (most people) is provided in a separate table above the COVID-19 vaccination schedule for moderately or severely immunocompromised people. The CDC maintains COVID-19 vaccination schedule for most people and people who are moderately or severely immunocompromised.

COVID-19 Vaccination Schedule for Moderately or Severely Immunocompromised Individuals
Vaccines against covid19* Approved ages Vaccination schedule
mRNA vaccines:**
Pfizer-BioNTech 6 months-4 years

3 doses total

Primary vaccination in 3 doses (3 weeks between doses 1 and 2; at least 8 weeks between doses 2 and 3)

A booster dose is currently not recommended

Pfizer-BioNTech 5-11 years old

4 doses total

Primary vaccination in 3 doses (3 weeks between doses 1 and 2; at least 4 weeks between doses 2 and 3)

A single booster dose recommended at least 3 months after the 3-dose primary series

Pfizer-BioNTech (Community) 12 years and over

5 doses total

Primary vaccination in 3 doses (3 weeks between doses 1 and 2; at least 4 weeks between doses 2 and 3)

First booster dose recommended at least 3 months after the 3-dose primary series

Recommended second booster dose using mRNA vaccine at least 4 months after first booster dose

Modern

6 months-17 years

3 doses total

Primary vaccination in 3 doses (4 weeks between doses 1 and 2; at least 4 weeks between doses 2 and 3)

A booster dose is currently not recommended

Modern (Spikevax) 18 and over

5 doses total

Primary vaccination in 3 doses (4 weeks between doses 1 and 2; at least 4 weeks between doses 2 and 3)

First booster dose recommended at least 3 months after primary vaccination

Recommended second booster dose using mRNA vaccine at least 4 months after first booster dose

Anyone unable or unwilling to receive the mRNA vaccine

Johnson and Johnson (Janssen)***

Viral vector vaccine

18 and over

4 total doses***

A primary vaccination in 2 doses is recommended

  • The first dose is the J&J vaccine
  • The second dose is recommended using an mRNA vaccine 4 weeks after the first dose of J&J

First booster (preferably mRNA) recommended at least 2 months after the second primary dose (mRNA)

Recommended second booster dose using mRNA vaccine at least 4 months after first mRNA booster dose

* The CDC recommends mRNA vaccines (Pfizer and Moderna) over the Johnson & Johnson (J&J)/Janssen COVID-19 vaccine for people age 18 and older. Anyone unable or unwilling to receive an mRNA vaccine can request the Johnson & Johnson COVID-19 vaccine. You can choose which COVID-19 vaccine to receive as the primary series and as the booster dose. Talk to your health care provider for further advice.

**Some people 12 years of age and older, particularly men 12-39 years of age, may wish to consult their healthcare professional about the length of the interval between the first and second dose of the vaccine series to mRNA based on the risk and benefit profile of the patient. (see CDC guidance for more information)

***The CDC is providing additional details to help Johnson and Johnson (Janssen) recipients complete the 4-dose regimen. See Appendix D, Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Licensed in the United States for more information.

Additional Resources (last updated 06/24/2022)

https://www.youtube.com/watch?v=videoseries

Add Comment